These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 29317734)

  • 1. Combined SEP and anti-PD-L1 antibody produces a synergistic antitumor effect in B16-F10 melanoma-bearing mice.
    Hu Z; Ye L; Xing Y; Hu J; Xi T
    Sci Rep; 2018 Jan; 8(1):217. PubMed ID: 29317734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Immunomodulatory Gallotanin-Rich Fraction From
    Lasso P; Gomez-Cadena A; Urueña C; Donda A; Martinez-Usatorre A; Romero P; Barreto A; Fiorentino S
    Front Immunol; 2020; 11():584959. PubMed ID: 33312174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCC0208025 (BMS202), a small molecule inhibitor of PD-L1, produces an antitumor effect in B16-F10 melanoma-bearing mice.
    Hu Z; Yu P; Du G; Wang W; Zhu H; Li N; Zhao H; Dong Z; Ye L; Tian J
    PLoS One; 2020; 15(3):e0228339. PubMed ID: 32214351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Treatment of Melanoma: Combined Parasite-Derived Peptide GK-1 and Anti-Programmed Death Ligand 1 Therapy.
    Vera-Aguilera J; Perez-Torres A; Beltran D; Villanueva-Ramos C; Wachtel M; Moreno-Aguilera E; Vera-Aguilera C; Ventolini G; Martínez-Zaguilán R; Sennoune SR
    Cancer Biother Radiopharm; 2017 Mar; 32(2):49-56. PubMed ID: 28301259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant effect of the novel TLR1/TLR2 agonist Diprovocim synergizes with anti-PD-L1 to eliminate melanoma in mice.
    Wang Y; Su L; Morin MD; Jones BT; Mifune Y; Shi H; Wang KW; Zhan X; Liu A; Wang J; Li X; Tang M; Ludwig S; Hildebrand S; Zhou K; Siegwart DJ; Moresco EMY; Zhang H; Boger DL; Beutler B
    Proc Natl Acad Sci U S A; 2018 Sep; 115(37):E8698-E8706. PubMed ID: 30150374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18.
    Ma Z; Li W; Yoshiya S; Xu Y; Hata M; El-Darawish Y; Markova T; Yamanishi K; Yamanishi H; Tahara H; Tanaka Y; Okamura H
    Clin Cancer Res; 2016 Jun; 22(12):2969-80. PubMed ID: 26755531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation.
    Reyes RM; Zhang C; Deng Y; Ji N; Mukherjee N; Padron AS; Clark CA; Svatek RS; Curiel TJ
    Oncoimmunology; 2021; 10(1):2006529. PubMed ID: 34858732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral injection of IFN-β induces chemokine production in melanoma and augments the therapeutic efficacy of anti-PD-L1 mAb.
    Uehara J; Ohkuri T; Kosaka A; Ishibashi K; Hirata Y; Ohara K; Nagato T; Oikawa K; Aoki N; Harabuchi Y; Ishida-Yamamoto A; Kobayashi H
    Biochem Biophys Res Commun; 2017 Aug; 490(2):521-527. PubMed ID: 28624449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B16 melanoma control by anti-PD-L1 requires CD8+ T cells and NK cells: application of anti-PD-L1 Abs and Trp2 peptide vaccines.
    Ji S; Lee J; Lee ES; Kim DH; Sin JI
    Hum Vaccin Immunother; 2021 Jul; 17(7):1910-1922. PubMed ID: 33522416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.
    Pilon-Thomas S; Mackay A; Vohra N; Mulé JJ
    J Immunol; 2010 Apr; 184(7):3442-9. PubMed ID: 20194714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultrasound targeting of microbubble-bound anti PD-L1 mAb to enhance anti-tumor effect of cisplatin in cervical cancer xenografts treatment.
    Ma Y; Han J; Jiang J; Zheng Z; Tan Y; Liu C; Zhao Y
    Life Sci; 2020 Dec; 262():118565. PubMed ID: 33038371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
    Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
    Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model.
    Kim KJ; Kim JH; Lee SJ; Lee EJ; Shin EC; Seong J
    Oncotarget; 2017 Jun; 8(25):41242-41255. PubMed ID: 28465485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a
    Ren J; Xu M; Chen J; Ding J; Wang P; Huo L; Li F; Liu Z
    Theranostics; 2021; 11(1):304-315. PubMed ID: 33391476
    [No Abstract]   [Full Text] [Related]  

  • 16. Enhancing CTL responses to melanoma cell vaccines in vivo: synergistic increases obtained using IFNgamma primed and IFNbeta treated B7-1+ B16-F10 melanoma cells.
    Dezfouli S; Hatzinisiriou I; Ralph SJ
    Immunol Cell Biol; 2003 Dec; 81(6):459-71. PubMed ID: 14636243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model.
    Molavi O; Ma Z; Hamdy S; Lai R; Lavasanifar A; Samuel J
    Immunol Cell Biol; 2008; 86(6):506-14. PubMed ID: 18392040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation.
    Reyes RM; Deng Y; Zhang D; Ji N; Mukherjee N; Wheeler K; Gupta HB; Padron AS; Kancharla A; Zhang C; Garcia M; Kornepati AVR; Boyman O; Conejo-Garcia JR; Svatek RS; Curiel TJ
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33849925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model.
    Merino M; Lozano T; Casares N; Lana H; Troconiz IF; Ten Hagen TLM; Kochan G; Berraondo P; Zalba S; Garrido MJ
    J Nanobiotechnology; 2021 Apr; 19(1):102. PubMed ID: 33849551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel form of immunotherapy using antigen peptides conjugated on PD-L1 antibody.
    Lee EJ; Jang GY; Lee SE; Lee JW; Han HD; Park YM; Kang TH
    Immunol Lett; 2021 Dec; 240():137-148. PubMed ID: 34710507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.